Valeant subsidiary Biovail to acquire Zovirax US, Canadian rights from GSK
The $300m transaction is expected to increase profitability of the brand for BLS which had previously been the exclusive distributor in the US, and expands BLS’ geographic rights
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.